53066-26-5 Usage
Description
Erythromycin A methoxime is a semisynthetic antibiotic derived from erythromycin. It has been modified to improve its pH stability and hydrophobicity, resulting in better in vivo absorption compared to its parent compound. Erythromycin A methoxime functions by binding to the ribosome at the polypeptide exit tunnel, thereby inhibiting protein synthesis.
Uses
Used in Pharmaceutical Industry:
Erythromycin A methoxime is used as an antibiotic for treating bacterial infections. Its improved pH stability and hydrophobicity allow for better absorption in the body, making it a more effective treatment option for various infections.
Used in Antiviral Treatments:
Erythromycin A methoxime is used as an antiviral agent in compositions and methods for treating viral infections. Although it was tested in clinical trials as a treatment for HIV, the formulations were discontinued.
Used in Broad-Spectrum Applications:
Erythromycin A methoxime, like other tetracyclines, exhibits broad-spectrum antibacterial and antiprotozoan activity. This makes it a versatile option for treating a wide range of infections caused by different types of pathogens.
Check Digit Verification of cas no
The CAS Registry Mumber 53066-26-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,3,0,6 and 6 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 53066-26:
(7*5)+(6*3)+(5*0)+(4*6)+(3*6)+(2*2)+(1*6)=105
105 % 10 = 5
So 53066-26-5 is a valid CAS Registry Number.
InChI:InChI=1/C38H70N2O13/c1-15-26-38(10,46)31(42)21(4)28(39-48-14)19(2)17-36(8,45)33(53-35-29(41)25(40(11)12)16-20(3)49-35)22(5)30(23(6)34(44)51-26)52-27-18-37(9,47-13)32(43)24(7)50-27/h19-27,29-33,35,41-43,45-46H,15-18H2,1-14H3/b39-28+/t19-,20?,21+,22?,23-,24?,25?,26-,27?,29?,30+,31-,32?,33-,35?,36-,37?,38-/m1/s1
53066-26-5Relevant articles and documents
The Conformation Analysis of Derivatives of Erythromycin A. X-Ray Crystallographic and Nuclear Magnetic Resonance Spectroscopic Studies of (E)-11-O-<2-Dimethylaminoethoxy)methyl-9-deoxo-9-methoxyiminoerythromycin A
Everett, Jeremy R.,Hatton, Ian K.,Hunt, Eric,Tyler, John W.,Williams, David J.
, p. 1719 - 1728 (2007/10/02)
(E)-11-O-(2-Dimethylaminoethoxy)methyl-9-deoxo-9-methoxyiminoerythromycin A (3) has been synthesised from erythromycin A (1) and its crystal structure conformation compared with that of (1).The conformations of the two sugars and their orientation with respect to one another are the same in (1) and (3).The conformations of the aglycones are, however, markedly different.In comparison with (1), the main conformational changes in (3) appear to be a folding in the aglycone about the C-7 methylene and lactone ring oxygen, which moves the C-6 hydroxy and lactone carbonyl away from the substituents at C-9 and C-11, and an inward folding (towards C-11) of the C-3 to C-5 region and the attached sugars.The conformation of (3) in CDCl3 was investigated by measuring 1H vicinal coupling constants, 1H n.O.e.s, and 13C spin-lattice relaxation times.These studies show that in solution (3) exists in a state of fast exchange between conformations of the C-3 to C-5 'folded out' and C3 to C-5 'folded in' types.One of the simplest representations of this would be a rapid equilibrium between conformations similar to those found in the crystal structures of (1) and (3).
